Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-1.4-2 | Award Amount: 15.57M | Year: 2010
The goal of VascuBone is to develop a tool box for bone regeneration, which on one hand fulfils basic requirements and on the other hand is freely combinable with what is needed in the respective patients situation. The tool box will include a variation of biocompatible biomaterials and cell types, FDA approved growth factors, material modification technologies, simulation and analytical tools like molecular imaging based in vivo diagnostics which can be combined for the specific medical need. This tool box will be used to develop translational approaches for regenerative therapies of three different types of bone defects. The chosen bone diseases differ in their requirements, to ensure a successful implementation and translation. Additionally this implementation strategy is characterized by high complexity to remove bottlenecks and limitations of bone regeneration identified in the clinical setting. Therefore definite quality criteria have to be evaluated concerning an optimal stem cell source/subpopulation as well as GF concentrations and their bioactivity in vivo. Furthermore quantitative evaluation will focus on the definition of differences between stem cell populations responsible for bone regeneration in young and old people, as a prerequisite for the development of regenerative therapies for the ageing European society. Considering a successful and prompt approval of the biomaterial, for each clinical application a minimum of modification steps in daily routine must be identified. The road map of the project and clinic trials contains pre-determined milestones, to ensure efficacy, safety, and immunological acceptance of the implant. The efficacy is quantified by high innovative MRI and PET/CT technology which is able to demonstrate the regenerative effect of biomaterials and cells in vivo. Based on the clinical data the proposal as Advanced Therapeutical Medicinal Product will be submitted to the European Medicines Agency at the end of the project.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.4-2 | Award Amount: 11.56M | Year: 2013
The NanoMag project is to improve and redefine existing analyzing methods and in some cases, to develop new analyzing methods for magnetic nanostructures. Using improved manufacturing technologies we will synthesize magnetic nanoparticles with specific properties that will be analyzed with a multitude of characterization techniques (focusing on both structural as well as magnetic properties) and bring the experimental results together to obtain a self-consistent picture which describes how structural and magnetic properties are interrelated. This extensive survey will be used to define standard measurements and techniques which are necessary for defining a magnetic nanostructure and quality control. NanoMag brings together Europes and internationally leading experts in; manufacturing of magnetic single-core nanoparticles and magnetic multi-core particles, analyzing and characterization of magnetic nanostructures and national metrology institutes. In the consortium we have gathered partners within research institutes, universities and metrology institutes, all carrying out front end research and developing applications in the field of magnetic nanoparticles.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.4-2 | Award Amount: 7.65M | Year: 2012
Regenerative medicine focuses on repairing or replacing tissue or organ function lost due to damage or congenital defects using appropriate cells for therapy that have healing capacities like stem cells or progenitor cells. Although regenerative medicine has the potential for more effective therapeutic interventions major improvement in three areas are still needed for a wider establishment of such new concepts in clinical practise: identification of the appropriate cells with healing capacity for the use in therapy, homing of these cells to the damaged tissue, and monitoring of the therapeutic intervention and effect. Thus, a multidisciplinary consortium has set up IDEA, a 60 month collaborative project to develop and establish: Photonic methods that allow a contact and marker-free identification and selection of cells with healing capacity for vascular, musculoskeletal and neuronal tissue defects; Magnetic cell select devices that capture and transport cells with healing potential through the circulatory system to damaged tissue and organs improving homing; Tracer and imaging technologies to monitor the therapeutic effects of interventional regenerative medicine by showing anatomic structure AND demonstrating cellular function using magnetic resonance imaging (MRI) and a new imaging technology known as magnetic particle imaging (MPI). The IDEA project is intended to provide collaboration between scientists and clinicians from Karolinska Institute (Stockholm, Sweden), Kings College (London, UK), Paracelsus Medical University (Salzburg, Austria) and Julius-Maximilians-University (Wrzburg, Germany) together with experts from SMEs specialized in photonic technologies for tissue engineering, medical device manufacturing with extensive experience in regulatory approval, the design, synthesis and up-scaling of nanoparticles for molecular imaging, and regulatory affairs. This multidisciplinary consortium will address scale-up, regulatory work and exploratory clinical investigations using the developed tools, technologies and devices in the time frame of the project.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP-2009-1.1-1 | Award Amount: 2.62M | Year: 2011
Nanoscience and nanotechnology are currently revolutionizing sectors such as medicine, information technologies, environmental or materials sciences, and creating new opportunities for our societies. In this context, magnetic nanoparticles (MNP) are key components to the development of novel nano- and biotechnologies. Magnetosomes are unique hybrid magnetic MNP produced by magnetotactic bacteria (MB). They are employed in applications ranging from extraction of DNA to the development of immunoassays and uses in spintronics are envisaged. However, only a very limited amount of MNP (few mg per day) can be formed by MB, and the formation principles remain to be tackled. Biomimetics, i.e. combining biological principles with chemistry, will pave the way to understand biomineralization of tailored MNP and to find out high-value high-yield synthetic routes to solve scientific and technological challenges. Specifically, we aspire at bridging the gap between different fields of science. For the first time, we will blend biological and genetic approaches with chemical and physical knowledge to understand the key parameters controlling the size, shape, composition and assembly of hybrid MNP in vivo and in vitro. We will combine nanoscience and nanotechnology to modify these properties and develop an ensemble of magnetic nanomaterials of higher values. This approach will lead to original contributions of innovative nature based on the combined skills of the partners to manufacture and characterize the biological, chemical, structural and magnetic properties of the MNP. The industrial partner will have key importance in managing and assessing the applicability of the MNP in Magnetic Resonance Imaging (MRI). Finally, our cell biologist partner will test the biocompatibility of the designed systems. In 3 years, we aim at being able to synthesize hybrid MNP with tailored magnetic and size properties by low-cost high-yield synthesis for applications in MRI.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.4-3 | Award Amount: 7.73M | Year: 2012
DARTRIX, DARPin Targeted RX (therapy) is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of glioblastoma. There is great need; glioblastoma is virtually incurable and most patients die within 12 months of diagnosis. DARPins are small, non-immunoglobulin human protein scaffolds that bind specific targets with exceptionally high-affinity. DARPins are amenable to GMP production and to scale-up. They are remarkably stable, even at high temperatures and they can be engineered to incorporate additional favourable properties to target glioblastoma cells with exceptionally high affinity. The new DARPins will be coupled to dextran-coated iron oxide nanoparticles, such as ferucarbotran or nanomag-MIP, which has been used clinically as a contrast agent for Magnetic Resonance Imaging (MRI). These particles are safe to use in patients and are traceable within the body. When stimulated by an appropriate alternating magnetic current, the particles generate heat that can kill cancer cells very effectively. The conjugation of DARPins with ferucarbotran or nanomag-MIP (DARTRIX particle) leads to a potent therapeutic by delivering targeted hyperthermia to glioblastoma. In addition, DARTRIX particle will be created economically, exploiting the fact that DARPins can be produced to GMP in gram quantities using E. coli. The DARTRIX particles will target to glioblastoma cells by virtue of the high affinity and specificity of DARPins and the particles will remain in place when heated. By using DARPins to target the DARTRIX particle to tumour cells before application of the magnetic current, it should be possible to generate toxic heat specifically in the tumour. The consortium has all the skills and knowledge to develop DARPins from bench-to-bedside for glioblastoma treatment. This DARTRIX particle will pioneer targeted hyperthermic cancer treatment of glioblastoma in an innovative adaptive first-in-man trial, using direct injection or convection enhanced delivery to localise the particles to the tumour.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.1.2-2 | Award Amount: 12.84M | Year: 2013
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented and provided evidence of efficacy of carriers and ligands. Over 5 years, NanoAthero will integrate GMP production, the initiation of clinical investigations in high-risk patients, including the preparation of regulatory dossiers, risk and ethical assessments, and the evaluation of the performance of optimized diagnostic and therapeutic compounds. NanoAthero offers a unique opportunity for combining in-depth knowledge of nanocarrier bioengineering and production with state-of the art expertise in imaging and treatment of cardiovascular patients providing a full bench-to-bedside framework within one collaborative consortium of 16 partners from academia, a European association, SMEs and a large pharmaceutical company. NanoAthero gathers together leading chemists, engineers, pharmacists, biologists, toxicologists, clinicians, analysts, ethicists and key-opinion leaders in the field of cardiovascular medicine and early drug development. In NanoAthero, the nanocarriers carrying compounds to visualize thrombus or vulnerable plaques, or to deliver therapeutic agents should be suitable for proof-of-concept in patients. Phase I clinical trials targeting pivotal pathways in atherothrombosis will be performed with nanosystems for diagnosis and treatment of carotid atheroma. NanoAthero aims to propose nanosystems for thrombus imaging, stroke treatment and plaque stabilization in high-risk patients. Molecular imaging and therapeutic treatments in NanoAthero are based on feasible approaches.
News Article | November 2, 2016
— The report "Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021", analyzes and studies the major market drivers, restraints/challenges, and opportunities. The global contrast media/contrast agents market has been segmented on the basis of type, route of administration, indication, procedure, application, and region. Based on type, the contrast media/contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, barium-based contrast media, and microbubble contrast media. In 2016, the iodinated contrast media segment is estimated to account for the largest share of the contrast media/contrast agents market, by type. However, the microbubble contrast media segment is expected to grow at the highest CAGR during the forecast period. The high growth of the microbubble segment can be attributed to the large number of on-going academic researches that are exploring various attributes of microbubbles in off-label indications for diagnosis as well as drug delivery. Based on procedure, the contrast media/contrast agents market is segmented into X-ray/computed tomography, magnetic resonance imaging, and ultrasound. Based on route of administration, the contrast media/contrast agents market has been segmented into oral, injectable, rectal, and urethral routes. In 2016, the injectable segment is expected to account for the largest share of the contrast media/contrast agents market. Growth in the injectable contrast media segment can be attributed to advancements in CT and MRI imaging technologies, which majorly use injectable contrast media. Based on indication, the contrast media/contrast agentsmarket is segmented into cardiovascular disorders, oncology, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. In 2016, the cardiovascular disorders segment is estimated to account for the largest share of the global contrast media/contrast agentsmarket. Improvements in cardiac MRI procedures in cath labs, favorable reimbursement policies for contrast media used in cardiovascular diagnosis, and strong healthcare infrastructure in countries like the U.S., Canada, the U.K., and Germany are some of the factors driving the growth of this segment. Based on procedure, the global contrast media/contrast agents market is segmented into X-ray/CT, MRI, and ultrasound. In 2016, the X-ray/CT segment is expected to account for the largest share of the contrast media/contrast agents market. However, the ultrasound segment is expected to register the highest CAGR during the forecast period. Development of microbubble contrast media for ultrasound, and large number of approvals for ultrasound contrast media in major markets such as the U.S., Europe, and Japan are some of the key factors driving the growth of this segment. Based on application, the global contrast media/contrast agents market has been segmented into radiology, interventional radiology, and interventional cardiology. In 2016, the radiology segment is estimated to account for the largest share of the contrast media/contrast agents market. The large share of this segment can be attributed to the growing number of diagnostic procedures/centers, coupled with the increasing disease burden on countries. North America, Europe, Asia-Pacific, and Rest of the World (RoW) are the regions considered for a geographic analysis of the global contrast media/contrast agents market. In 2016, North America is estimated to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the European market is expected to grow at the highest CAGR during the forecast period, and will also serve as a revenue pocket for companies offering contrast media/contrast agents in the near future. The prominent players in the global contrast media/contrast agents market include Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), and Bracco Imaging S.p.A. (Italy). These companies hold a dominant position in the contrast media/contrast agents market mainly due to their well-established presence in the field of genomics, presence in over 50 countries, high R&D investments, and strong sales and distribution force. Other players operating in this market include Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India). For more information, please visit http://www.marketsandmarkets.com/requestsample.asp?id=911
News Article | November 10, 2016
The global contrast media market is projected to reach USD 5.44 Billion by 2021 from USD 4.46 Billion in 2016 growing at a CAGR of 4.1% during the forecast period. This growth can be attributed to factors such as increasing approvals for contrast agents and increase in the number of public and private diagnostic centers to improve diagnostic imaging services are driving the demand of various diagnostic imaging modalities. Moreover, strong product pipelines of the market players, coupled with the increasing research studies regarding applications of various contrast agents, are expected to drive the market in the near future. Complete report on Contrast Media Market spread across 159 Pages, Profiling 11 Companies and Supported with 77 Tables and 41 Figures is now available at http://www.rnrmarketresearch.com/contrast-mediacontrast-agents-market-by-product-iodinated-gadolinium-barium-by-technique-x-ray-ct-mri-cath-lab-ultrasound-by-application-radiology-interventional-radiology-interven-market-report.html . Factors such as increasing approvals for contrast agents and increase in the number of public and private diagnostic centers to improve diagnostic imaging services are driving the demand of various diagnostic imaging modalities. Moreover, strong product pipelines of the market players, coupled with the increasing research studies regarding applications of various contrast agents, are expected to create opportunities for market growth in the near future. However side effects, adverse and allergic reactions associated with contrast agents are restraining the growth of the market to a certain extent. North America, Europe, Asia-Pacific, and Rest of the World (RoW) are the regions considered for a geographic analysis of the global market. In 2016, North America is estimated to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the Europe market is expected to grow at the highest CAGR during the forecast period, and also serve as a revenue pocket for companies offering contrast media/contrast agents in the near future. Interested in this report, Get sample copy of this research now In 2016, the iodinated contrast media segment expected to account for the largest share of the global contrast media market, among type of contrast media; the injectable contrast media segment is expected to account for the largest share of the global contrast media agents market, among the routes of administration; the X-ray/CT segment is expected to dominate the global contrast media market, among procedures; the cardiovascular disorders segment is expected to account for the largest share of the global contrast media market, among indications; and the radiology segment is expected to dominate the contrast media market, among applications. Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A. (Italy) in 2015. These companies are dominant in the market mainly due to their well-established presence in the field of contrast media, presence in over 50 countries, high R&D investments, and strong sales and distribution force. While the other players includes Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India). Click now for more information on this research of “Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021” report @ http://www.rnrmarketresearch.com/contacts/discount?rname=66961 . The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies such as product approvals, agreements, collaborations, contract, and partnerships; expansions; and other strategies (divestment, grant, insurance coverage approval and acquisition) to increase their market shares and establish a strong foothold in the contrast media market. Based on region, the global contrast media market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is estimated to account for the largest share, followed by Europe and Asia-Pacific. However, the European market is expected to grow at the highest CAGR during the forecast period, and will also serve as a revenue pocket for companies offering contrast media/contrast agents in the near future. The high growth in this region can be attributed to the increasing research & development investments by market players, increasing incidence and prevalence of cancer, and increasing number of MRI and CT scanners. Explore more reports on Biotechnology at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology .
News Article | October 31, 2016
This report studies sales (consumption) of Contrast Media in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Bayer HealthCare GE Healthcare Guerbet Group Bracco Imaging S.p.A. Lantheus Medical Imaging nanoPET Pharma GmbH CMC Contrast AB Daiichi Sankyo Subhra Pharma Private Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Contrast Media in these regions, from 2011 to 2021 (forecast), like USA China Europe Japan India Southeast Asia Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Iodinated Gadolinium Barium Microbubble Others Split by applications, this report focuses on sales, market share and growth rate of Contrast Media in each application, can be divided into Radiology Interventional Radiology Interventional Cardiology Others Global Contrast Media Sales Market Report 2016 1 Contrast Media Overview 1.1 Product Overview and Scope of Contrast Media 1.2 Classification of Contrast Media 1.2.1 Iodinated 1.2.2 Gadolinium 1.2.3 Barium 1.2.4 Microbubble 1.2.5 Others 1.3 Application of Contrast Media 1.3.1 Radiology 1.3.2 Interventional Radiology 1.3.3 Interventional Cardiology 1.3.4 Others 1.4 Contrast Media Market by Regions 1.4.1 USA Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 India Status and Prospect (2011-2021) 1.4.6 Southeast Asia Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Contrast Media (2011-2021) 1.5.1 Global Contrast Media Sales and Growth Rate (2011-2021) 1.5.2 Global Contrast Media Revenue and Growth Rate (2011-2021) 9 Global Contrast Media Manufacturers Analysis 9.1 Bayer HealthCare 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Contrast Media Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 9.1.3 Bayer HealthCare Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.1.4 Main Business/Business Overview 9.2 GE Healthcare 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 124 Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 9.2.3 GE Healthcare Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.2.4 Main Business/Business Overview 9.3 Guerbet Group 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 147 Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 9.3.3 Guerbet Group Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.3.4 Main Business/Business Overview 9.4 Bracco Imaging S.p.A. 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Oct Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 9.4.3 Bracco Imaging S.p.A. Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.4.4 Main Business/Business Overview 9.5 Lantheus Medical Imaging 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 9.5.3 Lantheus Medical Imaging Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.5.4 Main Business/Business Overview 9.6 nanoPET Pharma GmbH 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Million USD Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 9.6.3 nanoPET Pharma GmbH Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.6.4 Main Business/Business Overview 9.7 CMC Contrast AB 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Pharma & Healthcare Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 9.7.3 CMC Contrast AB Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.7.4 Main Business/Business Overview 9.8 Daiichi Sankyo 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 9.8.3 Daiichi Sankyo Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.8.4 Main Business/Business Overview 9.9 Subhra Pharma Private 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 9.9.3 Subhra Pharma Private Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016) 9.9.4 Main Business/Business Overview
Ludwig F.,TU Braunschweig |
Wawrzik T.,TU Braunschweig |
Yoshida T.,Kyushu University |
Gehrke N.,NanoPET Pharma GmbH |
And 3 more authors.
IEEE Transactions on Magnetics | Year: 2012
Systematic studies of the magnetic properties of magnetic nanoparticles from FeraSpin R and the FeraSpin Series with respect to their suitability as tracers for magnetic particle imaging are presented. Magnetic particle spectroscopy measurements indicate that FeraSpin R exhibits a harmonic spectrum very similar to that of Resovist, whereas FeraSpin L, XL, and XXL show a 2.5-fold increase of harmonic amplitudes compared to FeraSpin R. To understand the differences between the various samples of the FeraSpin Series, representing size-selected, narrowly distributed particles of identical composition extracted from FeraSpin R, measurements of the ac susceptibility (ACS), magnetorelaxometry (MRX), and static M-H curves were performed on suspended and immobilized particle samples. ACS and MRX measurements on immobilized samples indicate a wide distribution of anisotropy energies despite the narrow distribution of hydrodynamic sizes. Static magnetization measurements show that all samples exhibit a bimodal distribution of magnetic moments: The fraction of larger moments corresponds to the contribution from the overall particle core, whereas the smaller is attributed to the contribution from the crystallites comprising the core. © 2012 IEEE.